RamaZottius Lab - Company finances
|
EUR
|
2020
From: 2020-10-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|
|
Financial data
|
||||||
| Sales revenue | - | - | 10,450 | - | 16,000 | 2,500 |
| Profit before tax | - | - | - | - | 1,496 | -1,031 |
| Net profit | -986 | -38,919 | 8,098 | -8,741 | 1,496 | -1,031 |
| Equity | 2,014 | -34,951 | -28,513 | -28,456 | -1,134 | -2,166 |
| Liabilities | 122 | 36,023 | 47,587 | 37,060 | 19,072 | 13,078 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Current assets | 2,136 | 1,072 | 19,074 | 8,604 | 145 | 10,912 |
| Total assets | 2,136 | 1,072 | 19,074 | 8,604 | 145 | 10,912 |
|
Taxes paid
|
||||||
| STI taxes | - | - | - | 2,532 | 9,690 | 1,615 |
|
Financial indicators
|
||||||
| Revenue change y/y | - | - | - | - | - | -84.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -46.2% | -3630.5% | 42.5% | -101.6% | 1031.7% | -9.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -49.0% | - | - | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | - | 77.5% | - | 9.4% | -41.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | 9.4% | -41.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | - | - | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | 10,450 | - | 5,333 | 2,143 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
RamaZottius Lab - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-05-16 | 2024-05-28 | 769.49 |
| 2024-04-23 | 2024-05-15 | 0.13 |
| 2024-04-16 | 2024-04-18 | 444.63 |
| 2023-10-17 | 2023-10-17 | 991.51 |
| 2023-09-29 | 2023-10-16 | 276.93 |
| 2023-09-18 | 2023-09-28 | 341.40 |
| 2023-02-17 | 2023-04-12 | 0.46 |
| 2023-02-06 | 2023-02-12 | 0.46 |
| 2023-01-17 | 2023-02-03 | 0.46 |
| 2022-12-16 | 2023-01-12 | 0.46 |
| 2022-11-21 | 2022-12-13 | 0.46 |
| 2022-11-17 | 2022-11-18 | 0.46 |
| 2022-10-31 | 2022-11-13 | 0.46 |
| 2022-10-18 | 2022-10-30 | 0.44 |
| 2022-09-16 | 2022-10-10 | 0.44 |
| 2022-08-23 | 2022-09-06 | 0.44 |
| 2022-07-18 | 2022-07-20 | 6.07 |
| 2022-03-16 | 2022-03-17 | 0.90 |
| 2022-02-17 | 2022-03-13 | 0.90 |
| 2022-01-27 | 2022-02-10 | 0.90 |
| 2022-01-18 | 2022-01-26 | 0.13 |
| 2021-12-20 | 2022-01-10 | 0.13 |
RamaZottius Lab - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2024-12-13 | 2024-12-15 | 29.58 |
| 2024-10-12 | 2024-10-15 | 29.37 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
RamaZottius Lab, UAB, code 305621868, is a Private Limited Liability Company operating in the manufacture of other medical and dental devices, instruments and supplies. The latest financial year, 2025, shows a small business with €2.5K revenue and a net loss of €1.0K, which implies a negative profit margin of 41.2%. Performance weakened sharply year on year, as revenue fell by 84.4% from €16.0K in 2024, when the company reported net profit of €1.5K and a 9.3% margin. In 2023, it also recorded a net loss of €8.7K, indicating an uneven three-year trajectory with a brief return to profit in 2024 before slipping back into loss in 2025. The balance sheet remains stretched: total assets were €10.9K, equity stood at -€2.2K, and liabilities were €13.1K. Asset turnover was low, reflecting limited revenue generation from the asset base. Revenue per employee was €2.5K, while profit per employee was -€1.0K, pointing to weak productivity in 2025.